New York Stock ExchangeWIKIMEDIA, ARUN DE JOEThe first 31 days of 2014 were fruitful for biotech companies going public, according to the financial services firm Burrill & Company. In a statement, the firm noted that six life-sciences companies completed public offerings last month, raising a total of $439 million. Last year was also strong for biotech initial public offerings (IPOs), with six companies completing them in September alone.

“The strong start for biotech IPOs in 2014 reflects broad interest in the sector and the fact that biotech is outperforming the general markets,” CEO G. Steven Burrill said in the statement. “The enthusiasm at this year’s J.P. Morgan Healthcare Conference has refueled momentum in the sector and companies are seeking to take advantage of Wall Street’s still open arms.”

But while the biotech IPO drought of years past may have ended, experts warn that the perceived boom...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?